Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03336333
Recruitment Status : Recruiting
First Posted : November 8, 2017
Last Update Posted : October 1, 2020
Sponsor:
Information provided by (Responsible Party):
BeiGene

Brief Summary:
The primary objective of this study is to compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival.

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Drug: Zanubrutinib Drug: Bendamustine Drug: Rituximab Drug: Venetoclax Phase 3

Detailed Description:
This is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), including participants without del(17p) [Cohort 1] and participants with del(17p) [Cohort 2 and Cohort 3]. Participants in Cohort 1 are randomized 1:1 to zanubrutinib (Arm A) or bendamustine plus rituximab (Arm B). Randomization will be stratified by age, Binet stage, immunoglobulin variable region heavy chain (IGHV) mutational status, and geographic region. Participants in Cohort 2 will receive treatment with zanubrutinib. Participants in Cohort 3 will receive treatment with zanubrutinib and venetoclax.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 680 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Actual Study Start Date : November 2, 2017
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : October 2022


Arm Intervention/treatment
Experimental: Cohort 1: Zanubrutinib
Participants without del[17p] will receive zanubrutinib for up to six 28-day cycles
Drug: Zanubrutinib
Administered as two 80-mg capsules by mouth twice a day (160 mg twice a day)
Other Names:
  • BGB-3111
  • BRUKINSA

Experimental: Cohort 1: B+R
Participants without del[17p] will receive bendamustine plus rituximab for up to six 28-day cycles
Drug: Bendamustine
Administered intravenously (IV) at a dose of 90 mg/m2/day on the first 2 days of each cycle for 6 cycles.
Other Name: Treanda, Ribomustin, and Levact

Drug: Rituximab
Administered intravenously (IV) at a dose of 375 mg/m2 on day 0 of cycle 1, and at a dose of 500 mg/m2 on day 1 of cycles 2 to 6.
Other Name: Rituxan, MabThera

Experimental: Cohort 1a (China only): Zanubrutinib
Participants without del[17p] will receive zanubrutinib for up to six 28-day cycles
Drug: Zanubrutinib
Administered as two 80-mg capsules by mouth twice a day (160 mg twice a day)
Other Names:
  • BGB-3111
  • BRUKINSA

Experimental: Cohort 1a (China only): B+R
Participants without del[17p] will receive bendamustine plus rituximab for up to six 28-day cycles
Drug: Bendamustine
Administered intravenously (IV) at a dose of 90 mg/m2/day on the first 2 days of each cycle for 6 cycles.
Other Name: Treanda, Ribomustin, and Levact

Drug: Rituximab
Administered intravenously (IV) at a dose of 375 mg/m2 on day 0 of cycle 1, and at a dose of 500 mg/m2 on day 1 of cycles 2 to 6.
Other Name: Rituxan, MabThera

Experimental: Cohort 2: Zanubrutinib
Participants with del[17p] will receive zanubrutinib for up to six 28-day cycles
Drug: Zanubrutinib
Administered as two 80-mg capsules by mouth twice a day (160 mg twice a day)
Other Names:
  • BGB-3111
  • BRUKINSA

Experimental: Cohort 3: Venetoclax + zanubrutinib
Participants with del[17p] will receive venetoclax and zanubrutinib for up to six 28-day cycles
Drug: Zanubrutinib
Administered as two 80-mg capsules by mouth twice a day (160 mg twice a day)
Other Names:
  • BGB-3111
  • BRUKINSA

Drug: Venetoclax
400mg tablets administered orally once daily.
Other Name: Venclexta, Venclyxto




Primary Outcome Measures :
  1. Cohort 1: Progression-free survival (PFS) between treatment groups (Zanubrutinib vs. B+R) as determined by independent central review (ICR). [ Time Frame: Up to 5 years. ]

Secondary Outcome Measures :
  1. Cohort 1: Overall response rate (ORR) between treatment groups [ Time Frame: Up to 5 years. ]
  2. Pooled Cohort 1/1a: Overall response rate (ORR) between treatment groups [ Time Frame: Up to 5 years. ]
  3. Cohort 1: Overall survival (OS) between treatment groups [ Time Frame: Up to 5 years. ]
  4. Cohort 1: Duration of response (DOR) between treatment groups [ Time Frame: Up to 5 years. ]
  5. Pooled Cohort 1/1a: Duration of response (DOR) between treatment groups [ Time Frame: Up to 5 years. ]
  6. Cohort 1: Progression-free survival (PFS) between treatment groups determined by investigator assessment (IA). [ Time Frame: Up to 5 years. ]
  7. Pooled Cohort 1/1a: Progression-free survival (PFS) between treatment groups determined by investigator assessment (IA). [ Time Frame: Up to 5 years. ]
  8. Cohort 1: Patient-reported outcomes as assessed by the (European Quality Of Life 5D 5L) EQ-5D-5L questionnaire [ Time Frame: Up to 5 years. ]
  9. Cohort 1: Patient-reported outcomes as assessed by the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) questionnaire. [ Time Frame: Up to 5 years. ]
  10. Cohort 2: Overall response rate (ORR) [ Time Frame: Up to 5 years. ]
  11. Cohort 2: Progression-free survival (PFS) [ Time Frame: Up to 5 years. ]
  12. Cohort 2: Duration of response (DOR) [ Time Frame: Up to 5 years. ]
  13. Cohort 3: Overall response rate (ORR) [ Time Frame: Up to 5 years. ]
  14. Cohort 3: Progression-free survival (PFS) [ Time Frame: Up to 5 years. ]
  15. Cohort 3: Duration of response (DOR) [ Time Frame: Up to 5 years. ]
  16. Cohort 3: Rate of undetectable minimal residual disease (MRD4) [ Time Frame: Up to 5 years. ]
  17. Number of participants experiencing Adverse Events (AEs) [ Time Frame: Up to 5 years. ]
  18. Number of participants experiencing Serious Adverse Events (SAEs) [ Time Frame: Up to 5 years. ]
  19. Apparent rate of clearance of zanubrutinib from plasma (CL/F)CL/F [ Time Frame: Predose up to 12 hours postdose ]
  20. Cohort 1 Zanubrutinib only arms: Area-Under-Curve from time 0 to 12 hours postdose (AUC0-12) [ Time Frame: Predose up to 12 hours postdose ]
  21. Cohort 3: Area-Under-Curve from time 0 to 12 hours postdose (AUC0-12) of zanubrutinib [ Time Frame: Predose up to 12 hours postdose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Unsuitable for chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR)
  • Confirmed diagnosis of CD20-positive CLL or SLL, requiring treatment.
  • Measurable disease by imaging
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
  • Life expectancy ≥ 6 months.
  • Adequate bone marrow function.
  • Adequate renal and hepatic function.

Key Exclusion Criteria:

  • Previous systemic treatment for CLL/SLL.
  • Requires ongoing need for corticosteroid treatment.
  • Known prolymphocytic leukemia or history of or suspected Richter's transformation.
  • Clinically significant cardiovascular disease.
  • Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix of breast, or localized Gleason score 6 prostate cancer.
  • History of severe bleeding disorder.
  • History of stroke or intracranial hemorrhage within 6 months before the first dose of study drug.
  • Severe or debilitating pulmonary disease.
  • Inability to swallow capsules or disease affecting gastrointestinal function.
  • Active infection requiring systemic treatment.
  • Known central nervous system involvement by leukemia or lymphoma
  • Underlying medical condition that will render the administration of study drug hazardous or obscure interpretation of toxicity or AEs
  • Known infection with human immunodeficiency virus (HIV) or active hepatitis B or C infection.
  • Major surgery ≤ 4 weeks prior to start of study treatment.
  • Pregnant or nursing females.
  • Vaccination with live vaccine within 35 days prior to the first dose of study drug.
  • Ongoing alcohol or drug addiction
  • Known hypersensitivity to zanubrutinib, bendamustine, rituximab, or venetoclax (as applicable) or any other ingredients of the study drugs.
  • Requires ongoing treatment with strong cytochrome P450 (CYP3A) inhibitor or inducer.
  • Concurrent participation in another therapeutic clinical trial.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03336333


Contacts
Layout table for location contacts
Contact: BeiGene +1-877-828-5568 clinicaltrials@beigene.com

Locations
Show Show 160 study locations
Sponsors and Collaborators
BeiGene
Investigators
Layout table for investigator information
Study Director: Jason Paik, MD BeiGene
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: BeiGene
ClinicalTrials.gov Identifier: NCT03336333    
Other Study ID Numbers: BGB-3111-304
2017-001551-31 ( EudraCT Number )
CTR20190416 ( Registry Identifier: Center for drug evaluation, CFDA )
First Posted: November 8, 2017    Key Record Dates
Last Update Posted: October 1, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BeiGene:
zanubrutinib
BTK inhibitor
bendamustine
rituximab
venetoclax
BGB-3111
Phase 3
Additional relevant MeSH terms:
Layout table for MeSH terms
Venetoclax
Lymphoma
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Rituximab
Bendamustine Hydrochloride
Zanubrutinib
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Enzyme Inhibitors